Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study
Clinical and Experimental Dermatology · 2026
DOI: 10.1093/ced/llaf483 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Giuseppe Lauletta und 52 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Psoriasis, Spondylarthropathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background
Biologic therapies such as dupilumab and tralokinumab have greatly impacted the management of moderate-to-severe atopic dermatitis (AD). However, recent clinical observations have reported paradoxical adverse events, including psoriasis and seronegative spondyloarthropathy (SpA).
Objectives
To assess the incidence, clinical characteristics and management of psoriasis and SpA in patients with AD treated with dupilumab or tralokinumab in a real-world setting.
Methods
We conducted a multicentre retrospective observational study involving patients with AD receiving dupilumab or tralokinumab for ≥ 16 weeks between January 2019 and May 2025. Data were collected on patients developing psoriasis and/or SpA, including demographics, time to onset, severity, management strategies and treatment outcomes.
Results
Psoriasis developed in 78 of 5899 patients (1.3%) receiving dupilumab and 16 of 769 (2.1%) on tralokinumab, with respective mean times to onset of 57.7 (SD 66.5) and 28.3 (28.9) weeks. SpA occurred in 17 patients (0.3%) on dupilumab and 1 (0.1%) on tralokinumab. Topical calcipotriol/betamethasone was the most frequent treatment for psoriasis, while systemic agents, including methotrexate and corticosteroids, were required in refractory cases. In addition, a proportion of patients required switching to alternative biologics due to poor disease control. For SpA, management often involved systemic corticosteroids, nonsteroidal anti-inflammatory drugs or methotrexate, and upadacitinib was introduced in 41% of cases of dupilumab requiring therapeutic escalation.
Conclusions
Although rare, psoriasis and SpA are adverse events emerging during dupilumab or tralokinumab therapy in patients with AD. Close monitoring and prompt differential diagnosis are essential to optimize patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
- Department of Medicine and Health Sciences 'Vincenzo Tiberio', University of Molise, Campobasso, Italy.
ORCID-Profile: Giuseppe Lauletta, Luca Potestio, Francesca Barei, Luca Stingeni, Andrea Carugno, Claudio Marasca
Zitieren
APA
Lauletta, G., Patruno, C., Potestio, L., Ortoncelli, M., Ribero, S., Barei, F., Ferrucci, S. M., Bonzano, L., Trave, I., Guanti, M. B., Piraccini, B. M., Gurioli, C., Gori, N., Ippoliti, E., Peris, K., Grigolato, L., Rossi, M., Foti, C., Romita, P., …, & Napolitano, M. (2026). Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf483
Vancouver
Lauletta G, Patruno C, Potestio L, Ortoncelli M, Ribero S, Barei F, et al. Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llaf483
BibTeX
@article{Lauletta2026,
author = {Lauletta, Giuseppe and Patruno, Cataldo and Potestio, Luca and Ortoncelli, Michela and Ribero, Simone and Barei, Francesca and Ferrucci, Silvia Mariel and Bonzano, Laura and Trave, Ilaria and Guanti, Mario Bruno and Piraccini, Bianca Maria and Gurioli, Carlotta and Gori, Niccolò and Ippoliti, Elena and Peris, Ketty and Grigolato, Laura and Rossi, Mariateresa and Foti, Caterina and Romita, Paolo and Tirone, Benedetta and Nettis, Eustachio and Esposito, Maria and Fargnoli, Maria Concetta and Magnanimi, Lina Maria and Pezzolo, Elena and Hansel, Katharina and Stingeni, Luca and Satta, Rosanna and Mariano, Maria and Pigliacelli, Flavia and Manzo Margiotta, Flavia and Romanelli, Marco and Cascio Ingurgio, Ruggero and Costanzo, Antonio and Narcisi, Alessandra and Guglielmo, Alba and Schettini, Natale and Antiga, Emiliano and Morrone, Pietro and Rubegni, Pietro and Calabrese, Laura and Lazzeri, Laura and Guarneri, Fabrizio and Zerbinati, Nicola and Carugno, Andrea and Puca, Rosa Valentina and Sarno, Oriele and Marasca, Claudio and Musumeci, Maria Letizia and Micali, Giuseppe and Martina, Emanuela and De Lucia, Mario and Napolitano, Maddalena},
title = {Psoriasis and seronegative spondyloarthropathy in patients with atopic dermatitis treated with dupilumab or tralokinumab: a multicentre observational study},
journal = {Clinical and Experimental Dermatology},
year = {2026},
doi = {10.1093/ced/llaf483}
}
EUVIMED